Systems biology and combination therapy in the quest for clinical efficacy
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Background
Cited by
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845
“…example, aneffective drugcombination maytarget multiple proteinsor pathways that are aberrantly activated in disease, but not in normal cells, and thus reduces the chances that a cancer will develop drug resistance by activating bypassing pathways, when compared to standard mono-therapies [1 – 3].”
BackgroundLee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 680
“…interplay between signaling networks argues that a more systematic assessment exploring not only dosage, but also the order of drug presentation, scheduling, and dose duration might uncover cross-pathway effects and efficacious interactions that were missed previously (Fitzgerald et al., 2006).”
BackgroundInfluentialSelf-citationThe pharmaceutical industry and natural products: historical status and new trends
David, B., Wolfender, J.-L., & Dias, D. A. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-014-9367-z · Cited by 579
“Complex aspects (multi-component mixtures acting in complex biological systems) may be tackled by emerging systems biology approaches (Wang et al. 2005; Fitzgerald et al. 2006; Verpoorte 2012).”
BackgroundNetwork Pharmacology Approach for Medicinal Plants: Review and Assessment
Noor, F., Tahir ul Qamar, M., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022) · Pharmaceuticals · doi:10.3390/ph15050572 · Cited by 540
“Various active ingredients in medicinal plants have no more-robust connections with target proteins of the regulatory network; therefore, a synergistic approach is highly preferable that can switch off the action of harmful proteins, which in turn targets whole molecular networks that underlie the disease state [61,62…”
BackgroundMAP kinases and the control of nuclear events
Turjanski, A. G., Vaqué, J. P., & Gutkind, J. S. (2007) · Oncogene · doi:10.1038/sj.onc.1210415 · Cited by 432
“In fact, the simulation of MAPK networks suggests that the ultrasensitivity observed in MAPK cascades arise as a consequence of this two step phosphorylation process (Fitzgerald et al., 2006).”
BackgroundNew approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Li, S., Zhang, B., & Zhang, N. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-s1-s10 · Cited by 380
“The available evidences showed that molecular synergisms can be emerged from different aspects, for example, protein complexes in cell-regulatory systems [42], crosstalk [43-47] and feedback control in the structures of signal pathways [48,49], stimuli-influenced number of molecules (e.”
BackgroundNanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
Natural products for human health: an historical overview of the drug discovery approaches
Bernardini, S., Tiezzi, A., Laghezza Masci, V., & Ovidi, E. (2018) · Natural Product Research · doi:10.1080/14786419.2017.1356838 · Cited by 355
“…such as multi-component mixtures acting in biological systems, may be resolved by the emerging systems biology approaches (Wang et al. 2005; Fitzgerald et al. 2006; Verpoorte 2012); in particular, poly-pharmacology and synergism are building the new paradigm in NP drug discovery and…”
BackgroundSchoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 360
“HRG1-b abundance was quantified with a purified recombinant HRG1-b(1-246) protein (R&D, Systems 377-HB).”
MethodSelf-citationA community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321
“…synergy can potentially complement high-throughput synergy screens, but the few that have been published lack rigorous experimental validation or are appropriate only for compounds that modulate well-studied molecular pathways 15 or that are equivalent to previously established combinations 16 .”
BackgroundTriple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
A network view of disease and compound screening
Schadt, E. E., Friend, S. H., & Shaywitz, D. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2826 · Cited by 291
Oxysterols are allosteric activators of the oncoprotein Smoothened
Nachtergaele, S., Mydock, L. K., Krishnan, K., Rammohan, J., Schlesinger, P. H., Covey, D. F., & Rohatgi, R. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.765 · Cited by 284
NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning
Chen, X., Ren, B., Chen, M., Wang, Q., Zhang, L., & Yan, G. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004975 · Cited by 279
Farha, M. A., Verschoor, C. P., Bowdish, D., & Brown, E. D. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.07.006 · Cited by 278
“In fact, targeting redundancy and homeostasis is a critical feature of combinatorial therapy and at the root of successful combination therapies (Cottarel and Wierzbowski, 2007; Fitzgerald et al., 2006).”
BackgroundBotanical Drugs, Synergy, and Network Pharmacology: Forth and Back to Intelligent Mixtures
Gertsch, J. (2011) · Planta Medica · doi:10.1055/s-0030-1270904 · Cited by 212
“Multidrug combinations are vital in modern medicine [84].”
Trans-Omics: How To Reconstruct Biochemical Networks Across Multiple ‘Omic’ Layers
Yugi, K., Kubota, H., Hatano, A., & Kuroda, S. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.12.013 · Cited by 258
“Systems medicine aims to correct the behavior of a group of molecules by using pathway information [99,100], and is expected to change current reactive medicine, which is enacted after people contract disease, to predictive and personalized medicine based on genomic data [101–103].”
BackgroundXie, L., Li, J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000387 · Cited by 247
“Thus, a multiple-target approach [6] and combination therapy [10] have been actively pursued to boost clinical efficacy in the treatment of diseases such as cancer and diabetes.”
BackgroundA microfluidics platform for combinatorial drug screening on cancer biopsies
Eduati, F., Utharala, R., Madhavan, D., Neumann, U. P., Longerich, T., Cramer, T., Saez-Rodriguez, J., & Merten, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04919-w · Cited by 239
What is synergy? The Saariselkä agreement revisited
Tang, J., Wennerberg, K., & Aittokallio, T. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00181 · Cited by 217
“We review the theoretical relationships between these models and argue that one should combine the advantages of both models to provide a more consistent definition of synergy and antagonism.”
BackgroundMethodInfluentialCombinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
High-throughput kinase profiling as a platform for drug discovery
Goldstein, D. M., Gray, N. S., & Zarrinkar, P. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2541 · Cited by 215
“Even when inhibition of a single target might be effective, the understanding of cellular signalling networks is generally not quantitative enough to clearly define which kinase in a disease-implicated pathway may be the weak link and the most appropriate target, although the presence of activating mutations or gene a…”
BackgroundEvaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model
Liu, Q., Yin, X., Languino, L. R., & Altieri, D. C. (2018) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2018.1437071 · Cited by 208
“…years, many methods have been proposed (Loewe 1953; Bliss 1956; Carter et al. 1988; Berenbaum 1989; Greco, Par, and Rustum 1990; Machado and Robinson 1994; Greco, Bravo, and Parsons 1995; Dawson, Carter, and Gennings 2002; Chou 2006; Fitzgerald et al. 2006; Lee et al. 2007; Whitehead et al. 2008).”
MethodByun, J.-K., Park, M., Lee, S., Yun, J. W., Lee, J., Kim, J. S., Cho, S. J., Jeon, H.-J., Lee, I.-K., Choi, Y.-K., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.015 · Cited by 208
Pena-Miller, R., Laehnemann, D., Jansen, G., Fuentes-Hernandez, A., Rosenstiel, P., Schulenburg, H., & Beardmore, R. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001540 · Cited by 209
“Combinations said to be synergistic, where two drugs hit the pathogen much harder than each drug alone, are highly prized [1,12,13].”
BackgroundLiu, Q., & Xie, L. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1008653 · Cited by 203
High-Throughput Methods for Combinatorial Drug Discovery
Sun, X., Vilar, S., & Tatonetti, N. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006667 · Cited by 197
“An excellent discussion of pharmacological synergy, as well as the mathematical formulation of these models, is available in ( 29 ).”
BackgroundAn automated fitting procedure and software for dose-response curves with multiphasic features
Di Veroli, G. Y., Fornari, C., Goldlust, I., Mills, G., Koh, S. B., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2015) · Scientific Reports · doi:10.1038/srep14701 · Cited by 196
Large-scale exploration and analysis of drug combinations
Li, P., Huang, C., Fu, Y., Wang, J., Wu, Z., Ru, J., Zheng, C., Guo, Z., Chen, X., Zhou, W., et al. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv080 · Cited by 195
Perturbation Biology: Inferring Signaling Networks in Cellular Systems
Molinelli, E. J., Korkut, A., Wang, W., Miller, M. L., Gauthier, N. P., Jing, X., Kaushik, P., He, Q., Mills, G., Solit, D. B., et al. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003290 · Cited by 187
“the highly robust nature of the signaling pathways with multiple feedback mechanisms [9].”
BackgroundMorton, S. W., Lee, M. J., Deng, Z. J., Dreaden, E. C., Siouve, E., Shopsowitz, K. E., Shah, N. J., Yaffe, M. B., & Hammond, P. T. (2014) · Science Signaling · doi:10.1126/scisignal.2005261 · Cited by 190
“The complexity of growth, survival, and death signaling pathways in cancers continues to motivate investigation using systems biology approaches to inform treatments against cancer (4, 28).”
Chen, R., Zhang, J., Wang, Y., Chen, X., Zapien, J. A., & Lee, C.-S. (2015) · Nanoscale · doi:10.1039/c5nr04436g · Cited by 184
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
“…network organization suggests that judicious combinations of small molecule inhibitors of both essential and non-essential targets may elicit additive or synergistic effects on cell growth (Sharom et al, 2004; Agoston et al, 2005; Fitzgerald et al, 2006; Lehar et al, 2007, 2008; Hopkins, 2008).”
Geary, N. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00308.2012 · Cited by 165
Cirstea, D., Hideshima, T., Rodig, S., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., Perrone, G., Gorgun, G., Patel, K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0763 · Cited by 167
“Finally, using the in silico predictive analysis based on a systems biology approach (28, 29), we confirmed our experimental findings regarding the biological effects of this drug combination.”
MethodXie, L., Evangelidis, T., Xie, L., & Bourne, P. E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002037 · Cited by 165
“Perturbation may be achievable through the use of drug cocktails, or possibly through a single drug that has the appropriate polypharmacological effect [1,2,4,6,7,8,9,10,11].”
BackgroundSystems biology approaches for advancing the discovery of effective drug combinations
Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 159
“Drugs inhibiting parts of the same linear pathway may act according to Loewe additivity [17].”
BackgroundInfluentialOptimal Drug Synergy in Antimicrobial Treatments
Torella, J. P., Chait, R., & Kishony, R. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000796 · Cited by 162
“infection [1–5].”
Where is the hope for drug discovery? Let history tell the future
De, K., Li, X., & Zhang, H. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.002 · Cited by 179
Structure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 163
“The understanding of the drug response at the systems level is particularly important for understanding polypharmacology since there are many reported examples where the therapeutic efficacy is enhanced through synergistic relationships among multiple targets [107–111].”
BackgroundRorick‐Kehn, L. M., Witkin, J. M., Statnick, M. A., Eberle, E. L., McKinzie, J. H., Kahl, S. D., Forster, B. M., Wong, C. J., Li, X., Crile, R. S., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.021 · Cited by 166
“A synergy analysis was conducted using the method of Bliss Independence (Greco et al., 1995; Fitzgerald et al., 2006).”
Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008461 · Cited by 160
“Given a desired efficacy of the combination, arising from considerations, for instance, of achieving a desired decline in viral load [58], optimal drug dosages can be estimated that would maximize synergy while ensuring efficacy, as has been demonstrated in other settings [40,43,52,54,71].”
BackgroundInfluentialA compendium of kinetic modulatory profiles identifies ferroptosis regulators
Conlon, M., Poltorack, C. D., Forcina, G. C., Armenta, D. A., Mallais, M., Perez, M. A., Wells, A. C., Kahanu, A., Magtanong, L., Watts, J. L., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00751-4 · Cited by 155
Prediction of multidimensional drug dose responses based on measurements of drug pairs
Zimmer, A., Katzir, I., Dekel, E., Mayo, A. E., & Alon, U. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606301113 · Cited by 152
“To test this model, we begin by considering two-drug response surfaces (3, 45, 46).”
MethodAu-Yeung, G., Lang, F., Azar, W. J., Mitchell, C., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C., Pearson, R. B., Mileshkin, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 146
“Rational drug combinations are 103 a potential strategy to prevent resistance (15), and may also facilitate improvements in the 104 therapeutic window by reducing the doses of drugs required to achieve efficacy, resulting in 105 fewer side effects (16).”
Fröhlich, F., Kessler, T., Weindl, D., Shadrin, A., Schmiester, L., Hache, H., Muradyan, A., Schütte, M., Lim, J.-H., Heinig, M., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.013 · Cited by 143
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
BackgroundChemProt-3.0: a global chemical biology diseases mapping
Kringelum, J., Kjaerulff, S. K., Brunak, S., Lund, O., Oprea, T. I., & Taboureau, O. (2016) · Database · doi:10.1093/database/bav123 · Cited by 138
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 143
The Context-Dependence of Mutations: A Linkage of Formalisms
Poelwijk, F. J., Krishna, V., & Ranganathan, R. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004771 · Cited by 130
“With regard to human health, epistasis complicates our understanding of the origin and progression of disease [30–37].”
Network-based drug discovery by integrating systems biology and computational technologies
Leung, E. L., Cao, Z., Jiang, Z., Zhou, H., & Liu, L. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs043 · Cited by 152
Synergistic and Antagonistic Drug Combinations Depend on Network Topology
Yin, N., Ma, W., Pei, J., Ouyang, Q., Tang, C., & Lai, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093960 · Cited by 139
“Drug synergy, the combined boost of drug efficacy, is a highly pursued goal of combinational drug development [2].”
BackgroundLiu, J., Zhang, L., Lei, J., Shen, H., & Ju, H. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b14446 · Cited by 139
Combination antitumor therapy with targeted dual-nanomedicines
Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 147
“With an increasing understanding of complex, nonlinear and timedependent interplay between signaling networks, people become aware that the order of drug presentation and dose duration might affect the outcome of combination therapy with cytotoxic drugs and inhibitors on signaling pathways [118].”
BackgroundSun, Y., Sheng, Z., Ma, C., Tang, K., Zhu, R., Wu, Z., Shen, R., Feng, J., Wu, D., Huang, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9481 · Cited by 134
Systematic identification of synergistic drug pairs targeting HIV
Tan, X., Hu, L., Luquette, L. J., Gao, G., Liu, Y., Qu, H., Xi, R., Lu, Z. J., Park, P. J., & Elledge, S. J. (2012) · Nature Biotechnology · doi:10.1038/nbt.2391 · Cited by 131
A geometrical approach to control and controllability of nonlinear dynamical networks
Wang, L.-Z., Su, R.-Q., Huang, Z., Wang, X., Wang, W.-X., Grebogi, C., & Lai, Y. (2016) · Nature Communications · doi:10.1038/ncomms11323 · Cited by 153
Combinatorial drug discovery in nanoliter droplets
Kulesa, A. B., Kehe, J., Hurtado, J. E., Tawde, P., & Blainey, P. C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802233115 · Cited by 143
“We then split cultures between (1) Erlenmeyer flasks (10% of the flask volume, 37C, 220 RPM) and (2) droplets loaded into the microwell array (37C, no shaking).”
MethodInteraction Index and Different Methods for Determining Drug Interaction in Combination Therapy
Lee, J. J., Kong, M., Ayers, G. D., & Lotan, R. (2007) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400701199593 · Cited by 135
“The Bliss independence and Loewe additivity models are the two most cited reference models for defining drug interactions (Fitzgerald et al., 2006; Greco et al., 1995; Jonker et al., 2005).”
BackgroundSun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 147
“A Bliss combination index 53,54 was used to quantitatively evaluate the synergy produced by BRAF-I and MEK-I co-treatment and BRAF-I and PI3K-I co-treatment as follows: 50 .”
Pantuck, A. J., Lee, D., Kee, T., Wang, P., Lakhotia, S., Silverman, M. H., Mathis, C., Drakaki, A., Belldegrun, A. S., Ho, C., et al. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800104 · Cited by 127
Mechanism-independent method for predicting response to multidrug combinations in bacteria
Wood, K., Nishida, S., Sontag, E. D., & Cluzel, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201281109 · Cited by 135
Wang, H., Lee, D.-K., Chen, K., Chen, J.-Y., Zhang, K., Silva, A., Ho, C., & Ho, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b00638 · Cited by 134
“biology studies have shown that cellular pathways form complex networks and that their collective dynamics drive phenotypic outcomes.(5-10) Importantly, network dynamics cannot”
Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning
Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.003 · Cited by 121
“By analogy to the genetic networks that underpin biology, it should be possible to identify combinations of chemicals that mimic genetic interactions, such that compounds that cause minimal phenotypes alone exhibit strong synergies when combined (Sharom et al., 2004; Fitzgerald et al., 2006; Kitano, 2007; Roemer and B…”
Yuan, B., Shen, C., Luna, A., Korkut, A., Marks, D. S., Ingraham, J., & Sander, C. (2021) · Cell Systems · doi:10.1016/j.cels.2020.11.013 · Cited by 125
Systematic Quantification of Population Cell Death Kinetics in Mammalian Cells
Forcina, G. C., Conlon, M., Wells, A., Cao, J. Y., & Dixon, S. J. (2017) · Cell Systems · doi:10.1016/j.cels.2017.05.002 · Cited by 122
“Computing the expected effect of compound combinations is not trivial and there is no consensus about the best method to employ (Fitzgerald et al., 2006; Lehár et al., 2008).”
Harnessing synthetic lethality to predict the response to cancer treatment
Lee, J. S., Das, A., Jerby-Arnon, L., Arafeh, R., Auslander, N., Davidson, M., McGarry, L., James, D., Amzallag, A., Park, S. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04647-1 · Cited by 131
Modeling approaches for qualitative and semi-quantitative analysis of cellular signaling networks
Samaga, R., & Klamt, S. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-43 · Cited by 128
“These parallel pathways of the same sign may increase the system's robustness [54], but also resistance, for example, when cancer cells do not respond to (single) drugs because multiple pathways may still transduce an (aberrant) signal [55].”
BackgroundPeptidoglycan precursor synthesis along the sidewall of pole-growing mycobacteria
García-Heredia, A., Pohane, A. A., Melzer, E. S., Carr, C. R., Fiolek, T. J., Rundell, S. R., Lim, H. C., Wagner, J. C., Morita, Y. S., Swarts, B. M., et al. (2018) · eLife · doi:10.7554/elife.37243 · Cited by 115
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 120
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z., Chakraborty, A., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M. W., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 112
Gu, H., Liu, Zhang, J., Sun, Xie, & Xia (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s28088 · Cited by 132
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Olmez, I., Brenneman, B. R., Xiao, A., Serbulea, V., Benamar, M., Zhang, Y., Manigat, L. C., Abbas, T., Lee, J., Nakano, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0803 · Cited by 118
“The Bliss method was also used for synergy calculation as described previously (19).”
MethodMachine learning approaches for drug combination therapies
Güvenç Paltun, B., Kaski, S., & Mamitsuka, H. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab293 · Cited by 87
“Even though two drugs are not synergistic, they might still be beneficial by having higher efficacy and lower toxicity [24].”
BackgroundKirouac, D. C., Du, J. Y., Lahdenranta, J., Overland, R., Yarar, D., Paragas, V., Pace, E., McDonagh, C. F., Nielsen, U. B., & Onsum, M. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004008 · Cited by 105
“By simultaneously blocking functionally redundant pathways or cotargeting an adaptive feedback circuit along with the primary oncogenic driver, one could in theory substantially enhance efficacy and delay the onset of resistance (26).”
BackgroundSelf-citationImproving natural product research translation: From source to clinical trial
Sorkin, B. C., Kuszak, A. J., Bloss, G., Fukagawa, N. K., Hoffman, F. A., Jafari, M., Barrett, B. P., Brown, P. N., Bushman, F. D., Casper, S. J., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201902143r · Cited by 121
Systems Pharmacology: Defining the Interactions of Drug Combinations
van Hasselt, J. G. C., & Iyengar, R. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021511 · Cited by 110
Cytotoxic Effects of Plant Sap-Derived Extracellular Vesicles on Various Tumor Cell Types
Kim, K., Yoo, H. J., Jung, J., Lee, R., Hyun, J., Park, J., Na, D., & Yeon, J. H. (2020) · Journal of Functional Biomaterials · doi:10.3390/jfb11020022 · Cited by 109
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
El‐Hafeez, T. A., Shams, M. Y., Elshaier, Y. A. M. M., Farghaly, H. M., & Hassanien, A. E. (2024) · Scientific Reports · doi:10.1038/s41598-024-52814-w · Cited by 114
“can inhibit multiple targets, thereby overcoming drug resistance in infectious fungal diseases 5–7 .”
BackgroundThe promises of quantitative systems pharmacology modelling for drug development
Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L., & Le Novère, N. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.002 · Cited by 97
Network Propagation Predicts Drug Synergy in Cancers
Li, H., Li, T., Quang, D., & Guan, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0740 · Cited by 100
“This effect can be decomposed using the following equation: 𝐸(𝑎, 𝑏) = 𝐴(𝑎, 𝑏) + 𝑆(𝑎, 𝑏) where 𝐴(𝑎, 𝑏) is the additive effect and 𝑆(𝑎, 𝑏) is the synergistic effect, based on the definition using the Loewe model (28,29).”
MethodSearch Algorithms as a Framework for the Optimization of Drug Combinations
Calzolari, D., Bruschi, S., Coquin, L., Schofield, J., Feala, J. D., Reed, J. C., McCulloch, A. D., & Paternostro, G. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000249 · Cited by 101
“Several authors [4,5] have recently argued that the future of combination therapy lies in the development of accurate quantitative network models that capture the mechanistic interactions of cellular and organism physiology.”
BackgroundWitkin, J. M., Overshiner, C. D., Li, X., Catlow, J. T., Wishart, G. N., Schober, D. A., Heinz, B. A., Nikolayev, A., Tolstikov, V., Anderson, W. H., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216804 · Cited by 110
“analysis was conducted using the method of Bliss independence (Greco et al., 1995; Fitzgerald et al., 2006); using the end point of the”
MethodYang, L., Wu, D., Luo, K.-W., Wu, S., & Wu, P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.11.015 · Cited by 104
“Combination or multi-component therapy, in which one or more drugs are used at the same time, is the proven cure for cancers [14].”
BackgroundAdditive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition
Lederer, S., Dijkstra, T. M. H., & Heskes, T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00031 · Cited by 91
“This has its advantages in clinical trials, as a measure of success, such as synergy, does not need to be updated with biological advances (Fitzgerald et al., 2006).”
BackgroundUnderstanding resistance to combination chemotherapy
Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.003 · Cited by 108
“Systems perspectives in combination therapy There are many innovative perspectives on how systems/network biology might inform targeted cancer therapy, (Erler and Linding, 2010; Fitzgerald et al., 2006; Pawson and Linding, 2008).”
BackgroundProtein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses
Geva‐Zatorsky, N., Dekel, E., Cohen, A., Danon, T., Cohen, L., & Alon, U. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.011 · Cited by 111
“…or antagonism of drug effects and are compared to classical pharmacological models such as Bliss independence (Bliss, 1939), Loewe additivity (Loewe, 1953), and more elaborate functions (Fitzgerald et al., 2006; Potti et al., 2006; Yeh et al., 2006; Garman et al., 2007; Lehár et al., 2007).”
BackgroundInfluentialKorkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Onur Sumer, S., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 100
“One potential solution to overcome drug resistance is to combine targeted drugs to block potential escape routes (Fitzgerald et al., 2006).”
BackgroundA Computational Approach for Identifying Synergistic Drug Combinations
Gayvert, K. M., Aly, O., Platt, J., Bosenberg, M. W., Stern, D. F., & Elemento, O. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005308 · Cited by 97
Eduati, F., Doldàn-Martelli, V., Klinger, B., Cokelaer, T., Sieber, A., Kogera, F., Dorel, M., Garnett, M. J., Blüthgen, N., & Sáez-Rodríguez, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0078 · Cited by 104
“The understanding of mechanisms of cellular response (network structure and dynamic behavior) can also be useful to tackle the development of compensatory signaling mechanisms of drug resistance (14), which is a recurrent problem for targeted therapies and is challenging to predict.”
BackgroundDCDB: Drug combination database
Liu, Y., Hu, B., Fu, C., & Chen, X. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp697 · Cited by 95
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Wang, J., Hu, K., Guo, J., Cheng, F., Lv, J., Jiang, W., Lu, W., Liu, J., Pang, X., & Liu, M. (2016) · Nature Communications · doi:10.1038/ncomms11363 · Cited by 96
Identification of Potential Driver Genes in Human Liver Carcinoma by Genomewide Screening
Woo, H. G., Park, E. S., Lee, J., Lee, Y.-H., Ishikawa, T., Kim, Y. J., & Thorgeirsson, S. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0164 · Cited by 106
Baeder, D. Y., Yu, G., Hozé, N., Rolff, J., & Regoes, R. R. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0294 · Cited by 92
Guimerà, R., & Sales‐Pardo, M. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003374 · Cited by 101
“processes in which their targets are involved [6,14].”
Background
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.